Trade Names
Boniva; Bondronate.
Class and Category
Anti-osteoporotic. Bisphosphonate drug class.
Indications
Prevention and treatment of osteoporosis in postmenopausal women, demonstrated to reduce the incidence of new vertebral insufficiency fractures. Also used to treat metabolic bone disease associated with malignancy including hypercalcemia of malignancy and bone metastases of solid tumors.
Dosage
2.5 mg orally once daily, or variable dosing intravenously. Should be used in conjunction with adequate supplemental calcium and vitamin D.
Contraindications
Significant renal insufficiency; pregnancy; hypocalcemia.
Adverse Reactions
Dyspepsia, diarrhea, vomiting, gastritis, allergic reaction.
Drug Interactions
Aminoglycosides may lower serum calcium levels with prolonged administration; concomitant use may have additive effect. Increased risk of hypocalcemia with concomitant use of loop diuretics. Risk of renal dysfunction may be increased with concurrent use of thalidomide in patients...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adami S, et al (2002) Three-monthly 2mg intravenous ibandronate bolus injections significantly increase bone mineral density in women with postmenopausal osteoporosis. Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 036
Delmas P et al (2002) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study: Abstract presented at an oral presentation at the World Congress on Osteoporosis, May, Lisbon, Portugal, 037
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag
About this entry
Cite this entry
(2004). Ibandronate. In: Moreland, L.W. (eds) Rheumatology and Immunology Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29662-X_1315
Download citation
DOI: https://doi.org/10.1007/3-540-29662-X_1315
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20625-5
Online ISBN: 978-3-540-29662-1
eBook Packages: Springer Book Archive